Witnessing the stock’s movement on the chart, on Thursday, Intellia Therapeutics Inc (NASDAQ: NTLA) set off with pace as it heaved 2.54% to $11.29, before settling in for the price of $11.01 at the close. Taking a more long-term approach, NTLA posted a 52-week range of $9.25-$34.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 4.71% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -22.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.18%. This publicly-traded company’s shares outstanding now amounts to $101.80 million, simultaneously with a float of $99.79 million. The organization now has a market capitalization sitting at $1.15 billion. At the time of writing, stock’s 50-day Moving Average stood at $13.11, while the 200-day Moving Average is $20.00.
Intellia Therapeutics Inc (NTLA) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Intellia Therapeutics Inc’s current insider ownership accounts for 2.02%, in contrast to 92.52% institutional ownership. According to the most recent insider trade that took place on Jan 03 ’25, this organization’s VP, Chief Accounting Officer sold 1,372 shares at the rate of 12.18, making the entire transaction reach 16,711 in total value, affecting insider ownership by 45,640. Preceding that transaction, on Jan 03 ’25, Company’s EVP, General Counsel sold 7,074 for 12.18, making the whole transaction’s value amount to 86,161. This particular insider is now the holder of 74,497 in total.
Intellia Therapeutics Inc (NTLA) Earnings and Revenue Records
Intellia Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 2.18% and is forecasted to reach -5.15 in the upcoming year.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Let’s observe the current performance indicators for Intellia Therapeutics Inc (NTLA). It’s Quick Ratio in the last reported quarter now stands at 6.73. The Stock has managed to achieve an average true range (ATR) of 0.80. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 26.69.
In the same vein, NTLA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.45, a figure that is expected to reach -1.33 in the next quarter, and analysts are predicting that it will be -5.15 at the market close of one year from today.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Going through the that latest performance of [Intellia Therapeutics Inc, NTLA]. Its last 5-days volume of 3.58 million indicated improvement to the volume of 3.44 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 56.37% While, its Average True Range was 0.79.
Raw Stochastic average of Intellia Therapeutics Inc (NTLA) in the period of the previous 100 days is set at 14.06%, which indicates a major fall in contrast to 49.88% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 94.31% that was higher than 73.66% volatility it exhibited in the past 100-days period.
